Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprepitant versus ondansetron for prevention of postoperative nausea and vomiting after vitrectomy
IRCT20201116049410N3Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial in postoperative nausea and vomiting (PONV) comparing Ondansetron arm, Aprepitant arm and Placebo arm (3 arms). Primary endpoints: Postoperative nausea and vomiting, Oxygen saturation and 3 more. Started May 2026; status: completed.
02
Drugs
aprepitantondansetron
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on IRCT20201116049410N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201116049410N3.